Running a medical device clinical trial across Latin America means navigating four very different regulatory pathways — ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), and Panama MINSA. This 2026 guide from bioaccess®, a LATAM-focused CRO, breaks down submission requirements, realistic timelines, documentation, and the sequencing strategy sponsors use to run efficient multi-country early feasibility and pivotal studies.
Quick comparison: ANVISA vs COFEPRIS vs ANMAT vs Panama MINSA
| Agency | Country | Typical CT approval time | Ethics review | Import license |
|---|---|---|---|---|
| ANVISA | Brazil | 6–12 months | CONEP + local CEP | Yes (LI) |
| COFEPRIS | Mexico | 3–6 months | Local IRB + COFEPRIS | Yes |
| ANMAT | Argentina | 4–8 months | Local IRB + jurisdictional | Yes |
| Panama MINSA | Panama | 6–10 weeks | CNBI + local IRB | Yes |
ANVISA (Brazil) medical device clinical trial approval
ANVISA requires a Dossiê de Investigação Clínica de Dispositivo Médico (DICD) submission alongside CONEP ethics review. Sponsors must appoint a Brazilian legal representative and secure an import license (LI) for the investigational device. Expect 6–12 months end-to-end, with CONEP typically the critical-path node.
COFEPRIS (Mexico) medical device clinical trial approval
COFEPRIS runs a parallel scientific and ethics review. A Mexican sponsor representative and a certified local IRB are mandatory. Class III and implantable devices typically clear in 3–6 months. Import permits are issued per-shipment against the approved protocol.
ANMAT (Argentina) medical device clinical trial approval
ANMAT Disposición 4306/99 (and successor guidance) governs medical device trials. Provincial health authorities also review at the jurisdictional level, so timelines vary by province. Buenos Aires City and Province tend to be fastest. Plan 4–8 months from first submission to first-patient-in.
Panama MINSA medical device clinical trial approval
Panama is the LATAM speed play for early feasibility studies. MINSA’s Comité Nacional de Bioética de la Investigación (CNBI) plus a local IRB can deliver approval in 6–10 weeks for well-prepared dossiers. Ideal for first-in-human medical device studies where sponsors need real clinical data fast to support an FDA IDE or CE MDR submission.
Sequencing strategy: which country first?
For medical device sponsors targeting an FDA IDE or CE MDR submission, the pragmatic sequence is: Panama first (fastest FIH data), then Colombia and Mexico in parallel for scale, then Argentina and Brazil for pivotal-phase enrollment. This staggered approach compresses total time-to-evidence by 8–14 months versus a single-country pivot.
How bioaccess® supports multi-country LATAM submissions
bioaccess® is a LATAM-focused CRO with in-country regulatory teams across Colombia, Mexico, Panama, Argentina, and Brazil. We prepare harmonized dossiers, manage in-country legal representation, coordinate ethics submissions, and handle import logistics — so sponsors run one program, not five. Talk to our regulatory team to scope your LATAM strategy.
Leave a Reply